Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue -, Pages 117-122Publisher
WILEY-BLACKWELL
DOI: 10.1111/dom.12723
Keywords
aldehyde dehydrogenase; biomarker; genetics; human disease; lineage marker; progenitor cells; regeneration; therapeutic failure
Categories
Funding
- NIH [DK57539, DK63608, DK64819]
Ask authors/readers for more resources
Diabetes is caused by a combination of impaired responsiveness to insulin and reduced production of insulin by the pancreas. Until recently, the decline of insulin production had been ascribed to beta-cell death. But recent research has shown that beta-cells do not die in diabetes, but undergo a silencing process, termed dedifferentiation. The main implication of this discovery is that beta-cells can be revived by appropriate treatments. We have shown that mitochondrial abnormalities are a key step in the progression of beta-cell dysfunction towards dedifferentiation. In normal beta-cells, mitochondria generate energy required to sustain insulin production and its finely timed release in response to the body's nutritional status. A normal beta-cell can adapt its mitochondrial fuel source based on substrate availability, a concept known as metabolic flexibility. This capability is the first casualty in the progress of beta-cell failure. beta-Cells lose the ability to select the right fuel for mitochondrial energy production. Mitochondria become overloaded, and accumulate by-products derived from incomplete fuel utilization. Energy production stalls, and insulin production drops, setting the stage for dedifferentiation. The ultimate goal of these investigations is to explore novel treatment paradigms that will benefit people with diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available